Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of BNA035 in Advanced Solid Tumors
NCT05150457Phase 1Recruiting
- Sponsor
- Binacea Pharma
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HLX35 in solid tumor (6 arms), sponsored by Binacea Pharma. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose at 28 days and Incidence of Treatment-Emergent Adverse Events. Started Feb 2022; status: recruiting.
02
Drugs
HLX35
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05150457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150457.